A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label Phase 1b study of SLC-0111 (oral) in combination with IV
gemcitabine in CA IX positive subjects with mPDAC and comprises of 2 parts:
- Part 1: Dose Escalation
- Part 2: Dose Expansion
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
British Columbia Cancer Agency
Collaborators:
Canadian Cancer Society (CCS) Canadian Cancer Society Research Institute (CCSRI) Welichem Biotech Inc.